Advertisement

Table of Contents

What We're Reading

Cancer Immunology Miniatures

Priority Brief

  • Priority Brief
    Remodeling Translation Primes CD8+ T-cell Antitumor Immunity
    Katie E. Hurst, Kiley A. Lawrence, Rob A. Robino, Lauren E. Ball, Dongjun Chung and Jessica E. Thaxton
    Cancer Immunol Res May 1 2020 8 (5) 587-595; DOI:10.1158/2326-6066.CIR-19-0516

    Altering protein translation in T cells can affect their antitumor function. IL15-conditioned T cells have diminished protein translation in vitro but reinvigorate translation in tumors, a property that is attributed to T cells that produce superior tumor control.

Research Articles

  • Research Articles
    A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation
    Danica Chiu, Richard Tavaré, Lauric Haber, Olulanu H. Aina, Kristin Vazzana, Priyanka Ram, Makenzie Danton, Jennifer Finney, Sumreen Jalal, Pamela Krueger, Jason T. Giurleo, Dangshe Ma, Eric Smith, Gavin Thurston, Jessica R. Kirshner and Alison Crawford
    Cancer Immunol Res May 1 2020 8 (5) 596-608; DOI:10.1158/2326-6066.CIR-19-0518

    A CD3 bispecific antibody that targets a prostate tumor antigen elicits effective antitumor responses against smaller, but not larger, solid tumors. Addition of 4-1BB controls tumors through enhanced T-cell responses, T-cell memory formation, and response persistence.

  • Research Articles
    Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer
    Nitya Nair, Shih-Yu Chen, Ed Lemmens, Serena Chang, Dung T. Le, Elizabeth M. Jaffee, Aimee Murphy, Chan Whiting, Thomas Müller and Dirk G. Brockstedt
    Cancer Immunol Res May 1 2020 8 (5) 609-617; DOI:10.1158/2326-6066.CIR-19-0650

    Circulating immune subsets that associate with survival in pancreatic cancer patients treated with GVAX pancreas and/or CRS-207 immunotherapy are identified. These immune subsets can potentially be used as biomarkers to stratify patients most likely to respond to treatment.

  • Research Articles
    Deciphering the Immunomodulatory Capacity of Oncolytic Vaccinia Virus to Enhance the Immune Response to Breast Cancer
    Brittany A. Umer, Ryan S. Noyce, Brian C. Franczak, Mira M. Shenouda, Rees G. Kelly, Nicole A. Favis, Megan Desaulniers, Troy A. Baldwin, Mary M. Hitt and David H. Evans
    Cancer Immunol Res May 1 2020 8 (5) 618-631; DOI:10.1158/2326-6066.CIR-19-0703

    Genomic alterations of oncolytic viruses can improve their antitumor efficacy. Various genomic alterations of VACV are tested “head-to-head” in order to determine their impact on antitumor efficacy and immunity in murine tumor models.

  • Research Articles
    Intratumoral Delivery of a PD-1–Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade
    Chaolong Lin, Wenfeng Ren, Yong Luo, Shaopeng Li, Yating Chang, Lu Li, Dan Xiong, Xiaoxuan Huang, Zilong Xu, Zeng Yu, Yingbin Wang, Jun Zhang, Chenghao Huang and Ningshao Xia
    Cancer Immunol Res May 1 2020 8 (5) 632-647; DOI:10.1158/2326-6066.CIR-19-0628

    Oncolytic virus activity is often limited by an immunosuppressive tumor microenvironment. The antitumor efficacy of oncolytic herpes simplex virus is improved by delivering a single-chain variable fragment specific for PD-1. Pairing this with TIGIT blockade enhances antitumor responses.

  • Research Articles
    Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8+ T Cells within Polyomavirus-Driven Merkel Cell Carcinomas
    Lichen Jing, Mariliis Ott, Candice D. Church, Rima M. Kulikauskas, Dafina Ibrani, Jayasri G. Iyer, Olga K. Afanasiev, Aric Colunga, Maclean M. Cook, Hong Xie, Alexander L. Greninger, Kelly G. Paulson, Aude G. Chapuis, Shailender Bhatia, Paul Nghiem and David M. Koelle
    Cancer Immunol Res May 1 2020 8 (5) 648-659; DOI:10.1158/2326-6066.CIR-19-0647

    Merkel cell carcinoma is frequently associated with Merkel cell polyomavirus infection. Most patients' tumors contain virus-specific CD8+ T cells restricted by specific HLAs, highlighting the potential of using vaccination as part of immunotherapy strategies for this cancer.

  • Research Articles
    IL1α Antagonizes IL1β and Promotes Adaptive Immune Rejection of Malignant Tumors
    Tian Tian, Serena Lofftus, Youdong Pan, Claire A. Stingley, Sandra L. King, Jingxia Zhao, Timothy Y. Pan, Rebecca Lock, Jacob W. Marglous, Kevin Liu, Hans R. Widlund, Robert C. Fuhlbrigge, Karen Cichowski and Thomas S. Kupper
    Cancer Immunol Res May 1 2020 8 (5) 660-671; DOI:10.1158/2326-6066.CIR-19-0552

    Antibodies to IL1β can enhance antitumor immunity, but inhibiting IL1α reduces antitumor effects. Thus, antagonists that block the shared IL1R1 do not improve antitumor immunity and are not equivalent to blocking IL1β alone.

  • Research Articles
    Identification of the Targets of T-cell Receptor Therapeutic Agents and Cells by Use of a High-Throughput Genetic Platform
    Ron S. Gejman, Heather F. Jones, Martin G. Klatt, Aaron Y. Chang, Claire Y. Oh, Smita S. Chandran, Tatiana Korontsvit, Viktoriya Zakahleva, Tao Dao, Christopher A. Klebanoff and David A. Scheinberg
    Cancer Immunol Res May 1 2020 8 (5) 672-684; DOI:10.1158/2326-6066.CIR-19-0745

    The cross-reactivity of TCR-based therapies can lead to serious adverse events. PresentER is a high-throughput method for producing MHC-I peptide minigenes that can be used in in vitro immune assays to identify cross-reactive TCRs.

  • Research Articles | AuthorChoice
    Enhanced Immunogenicity of Mitochondrial-Localized Proteins in Cancer Cells
    Gennaro Prota, Uzi Gileadi, Margarida Rei, Ana Victoria Lechuga-Vieco, Ji-Li Chen, Silvia Galiani, Melissa Bedard, Vivian Wing Chong Lau, Lorenzo F. Fanchi, Mara Artibani, Zhiyuan Hu, Siamon Gordon, Jan Rehwinkel, Jose A. Enríquez, Ahmed A. Ahmed, Ton N. Schumacher and Vincenzo Cerundolo
    Cancer Immunol Res May 1 2020 8 (5) 685-697; DOI:10.1158/2326-6066.CIR-19-0467

    Compared to cytosolic antigens, mitochondrial tumor antigens prime a stronger antitumor immune response, instigated by enhanced cross-presentation and involvement of the STING pathway. Thus, cellular location of tumor antigens is relevant to improved cancer vaccine development.

  • Research Articles
    GITR Agonism Triggers Antitumor Immune Responses through IL21-Expressing Follicular Helper T Cells
    Choong-Hyun Koh, Il-Kyu Kim, Kwang-Soo Shin, Insu Jeon, Boyeong Song, Jeong-Mi Lee, Eun-Ah Bae, Hyungseok Seo, Tae-Seung Kang, Byung-Seok Kim, Yeonseok Chung and Chang-Yuil Kang
    Cancer Immunol Res May 1 2020 8 (5) 698-709; DOI:10.1158/2326-6066.CIR-19-0748

    Agonistic antibodies to GITR have antitumor effects. IL4-exposed CD4+ T cells activate c-Maf to generate IL21-expressing Tfh cells, which is required for antitumor activity and may be a surrogate marker for the effectiveness of GITR agonistic antibodies.

  • Research Articles
    RIPK3 Orchestrates Fatty Acid Metabolism in Tumor-Associated Macrophages and Hepatocarcinogenesis
    Lei Wu, Xiao Zhang, Lu Zheng, Huakan Zhao, Guifang Yan, Qi Zhang, Yu Zhou, Juan Lei, Jiangang Zhang, Jingchun Wang, Rong Xin, Lu Jiang, Jin Peng, Qian Chen, Sin Man Lam, Guanghou Shui, Hongming Miao and Yongsheng Li
    Cancer Immunol Res May 1 2020 8 (5) 710-721; DOI:10.1158/2326-6066.CIR-19-0261

    The immune-suppressive effects of tumor-associated macrophages (TAM) are partially controlled by metabolic reprogramming. RIPK3 shifts TAMs to an antitumor phenotype in hepatocellular carcinoma by modulating fatty acid metabolism, thus decreasing tumorigenesis.

Back to top

Jump to

Advertisement